Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor co-agonist, has demonstrated significant efficacy in the management of obesity and type 2 diabetes. However, its use can be associated with severe gastrointestinal (GI)-related adverse effects. This case report describes a 38-year-old male who developed severe vomiting and

Thrombolysis and thrombectomy in an extensive Portal Vein Thrombosis without underlying liver disease – A case report.Dr. Mohammadshah Isam Gula, Dr. Waseem Umera, Ahmed Daniyal Nawazc, Dr. Mohammad J H Elhissib, Dr. Muhammad Zahida,c,dInternal Medicine Department, Hamad Medical Corporation, Doha, QatarRadiology Department, Hamad Medical Corporation, Doha, QatarQatar University, Doha, QatarWeill Cornell Medicine, Doha, Qatar